scholarly journals Chemopreventive Effects of Propolis in the MNU-Induced Rat Mammary Tumor Model

2020 ◽  
Vol 2020 ◽  
pp. 1-13
Author(s):  
A. F. Gal ◽  
L. Stan ◽  
F. Tăbăran ◽  
D. Rugină ◽  
A. F. Cătoi ◽  
...  
Keyword(s):  
Tumor Model ◽  
Propolis Extract ◽  
Cancer Management ◽  
Mammary Tumor Model ◽  
Healing Agent ◽  
Physical Attributes ◽  
Rat Mammary Tumor ◽  
Ancient Times ◽  
Group 2 ◽  
Group 1

Currently, one of the central problems in cancer management is the relapse of disease following conventional treatments, yet few therapeutic agents targeting resistance and tolerance exist. Propolis is known as a healing agent since ancient times. Therefore, over time, its curative properties have kept the interest of scientists, thus leading permanently to investigations of its other possible undiscovered effects. In this context, current experiments were performed to establish the chemopreventive potential of propolis extract (PE) (1.05 mg/kg BW/day) in N-methyl-N-nitrosourea- (MNU-) induced rat mammary tumors. MNU-inoculated/PE-treated rats had tumors of different physical attributes compared with control rats MNU-inoculated. The number of developed tumors (mean 49% versus 100%), incidence (mean 49% versus 100%), multiplicity (1.8 versus 3.7 (p<0.001)), tumor volume (mean 10 cm3 versus 16 cm3 (p<0.001)), and weight of the tumor mass (mean 7.42 g versus 9.00 g (p<0.05)) were noted. The numbers of grade I tumors recorded for MNU-inoculated rats were 24 (Group 1) and 7 (Group 2) for MNU-induced/PE-treated rats. In the serum of rats MNU-inoculated/PE-treated were found higher levels of antioxidative enzymes (SOD, CAT, and GPx) than in MNU-induced. Taken together, these data indicate that propolis could be a chemopreventive agent against MNU-induced mammary carcinogenesis.

Immunomodulatory effects of a bioactive fraction of Strobilanthes crispus in NMU-induced rat mammary tumor model

2018 ◽  
Vol 213 ◽  
pp. 31-37 ◽  
Author(s):  
Hassan Muhammad Yankuzo ◽  
Yusha’u Shu’aibu Baraya ◽  
Zulkarnain Mustapha ◽  
Kah Keng Wong ◽  
Nik Soriani Yaacob
Keyword(s):  
Mammary Tumor ◽  
Tumor Model ◽  
Immunomodulatory Effects ◽  
Strobilanthes Crispus ◽  
Mammary Tumor Model ◽  
Rat Mammary Tumor ◽  
Bioactive Fraction

Cellular andIn Vivo characterization of the MCR rat mammary tumor model

1993 ◽  
Vol 53 (3) ◽  
pp. 486-492
Author(s):  
Alois Gutzwiller ◽  
Urs Regenass ◽  
Alex Matter ◽  
Nicholas B. Lydon
Keyword(s):  
Mammary Tumor ◽  
Tumor Model ◽  
Mammary Tumor Model ◽  
Rat Mammary Tumor

VRP immunotherapy targeting neu: treatment efficacy and evidence for immunoediting in a stringent rat mammary tumor model

2007 ◽  
Vol 106 (3) ◽  
pp. 371-382 ◽  
Author(s):  
Amanda K. Laust ◽  
Brandon W. Sur ◽  
Kehui Wang ◽  
Bolyn Hubby ◽  
Jonathan F. Smith ◽  
...  
Keyword(s):  
Mammary Tumor ◽  
Treatment Efficacy ◽  
Tumor Model ◽  
Mammary Tumor Model ◽  
Rat Mammary Tumor

How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer?

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e18708-e18708
Author(s):  
Anees B. Chagpar ◽  
Donald R. Lannin ◽  
Sarah Schellhorn Mougalian ◽  
Elizabeth Rapp Berger ◽  
Cary Philip Gross ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Therapy ◽  
Metastatic Breast ◽  
Practice Setting ◽  
Cancer Management ◽  
Group 3 ◽  
Group 2 ◽  
One Year ◽  
The Impact ◽  
Group 1

e18708 Background: The COVID-19 pandemic has caused shifts in terms of cancer management, but the impact of this has not been well-elucidated in a contemporary cohort of patients in clinical practice in the US. We hypothesized that closure of operating rooms would increase the use of neoadjuvant therapy (NT) during the early pandemic period. Methods: The nationwide Flatiron Health database is a longitudinal electronic health record (EHR)-derived database, comprising de-identified, patient-level structured and unstructured data, curated via technology-enabled abstraction. These data originated from approximately 280 cancer clinics. We compared patients diagnosed with non-metastatic breast cancer during the early pandemic period (March 1 – June 30, 2020; group 1) with those diagnosed in the four month period prior (November 1, 2019 – February 29, 2020; group 2) and those diagnosed during the same period one year earlier (March 1 – June 30, 2019; group 3). Results: There were 174 patients in group 1, 277 in group 2, and 348 in group 3. Overall, 591 (74.1%) were ER/PR+HER2-, 100 (12.6%) were HER2+, and 106 (13.3%) were triple negative (TN). Patients in the three groups were equally likely to be ER/PR+HER2- (75.3% vs. 72.2% vs. 74.9%, p = 0.68), HER2+ (12.1% vs. 14.9% vs. 11%, p = 0.33), TN (12.6% vs. 12.7% vs. 14.2%, p = 0.83) and to be high risk by genomic testing (either Oncotype Dx or Mammaprint; p = 0.72). While there was no difference in the clinical stage (p = 0.36) nor patient age at diagnosis (p = 0.76) across the three groups, patients diagnosed during the early pandemic (group 1) were more likely to receive NT compared to those diagnosed one year earlier (group 3); 28.7% vs 16.4%, p < 0.01 (see table). The use of NT differed between the three groups in the ER/PR+her2- (p < 0.01) and her2+ patients (p = 0.05), but not in the TN patients (p = 0.61). There was no difference in the use of NT overall during the pandemic by geographic state (p = 0.32) nor practice setting (p = 0.23); NT was also similar by geographic state and practice setting when considering the ER/PR+HER2-, HER2+, and TNBC subsets. Conclusions: Despite similar clinicopathologic features as earlier time periods, there was an increased use of NT during the early pandemic when compared to the same period in the prior year. This was seen particularly in the ER/PR+HER2- group, suggesting an increased use of neoadjuvant endocrine therapy.[Table: see text]

Sign in / Sign up

Export Citation Format

Share Document